Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.

By A. Renehan, Marcel Zwahlen, C. Minder, S. O'dwyer, S. Shalet, Matthias Egger. The Lancet, 2004

1,678 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Oncology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/47a3ef9fd3b481c1d8c1c91c15202dab4ed4ab50

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Antonio Ceriello
2. M. H. Murad
3. W. Willett
4. F. B. Hu
5. Vasanti S. Malik

In Oncology

1. W. Willett

In Public Health, Environmental and Occupational Health

1. J. Brand-Miller
2. Antonio Ceriello
3. W. Willett
4. Chris Feudtner
5. F. B. Hu
6. F. B. Hu
7. Vasanti S. Malik

Citations in the corpus

• Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) (2010, result): “That this increased risk might be related to serum growth hormone and/or IGF-1 levels is supported by recent epidemiological studies in the non-acromegalic population that have demonstrated an association between serum IGF-1 levels and risk of colorectal cancer.”
• Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). (2015, positive): “Insulin acts as a growth factor increasing the bioactivity of the cancer-promoting insulin-like growth factor-1 (IGF-1) which has proliferatory, angiogenic, anti-apoptotic and estrogen-stimulating properties [94,95].”
• Shared Risk Factors in Cardiovascular Disease and Cancer (2016, background): “menopausal breast cancer associated with high serum levels of IGF.(46,47) Hyperinsulinemia also decreases hepatic synthesis”
• Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency (2016, background): “, molar ratio of IGF-I/IGFBP-3 as an estimation of free IGF-I) to predict longterm risks [105-107].”
• Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies (2013, background): “Circulating total IGF-I, a major determinant of free IGF-I concentrations, is associated with increased risk of colorectal advanced adenomas and cancer [59,60].”
• Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics and Effect on the Insulin-like Growth Factor Axis (2010, neutral): “0g: 42 (21-73); body mass index (in kg/m(2)): 0.”
• The Role of Resveratrol in Cancer Therapy (2017, background): “Circulating concentrations of insulin-like growth factor (IGF-1) and IGF-binding protein 3 (IGFBP-3) are linked to a higher risk of common cancers [334].”
• Obesity and cancer risk: Emerging biological mechanisms and perspectives. (2019, neutral): “particularly prostate, colorectal and breast cancer [59-63].”